Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets
Neuro-Oncology · 21.06.2025 · 27 (5) · 1372-1384
DOI: 10.1093/neuonc/noaf012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 18.01.2025. Verfasst von Nathan M Kendsersky und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Immunotherapy, Cell Lineage, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Giulio D'Angio Endowed Chair, Cancer Pediatric Dream Team Translational Research Grant.
Abstract (Originalsprache)
Background
Neuroblastoma is a heterogeneous disease with adrenergic (ADRN)-like cells and therapy-resistant mesenchymal (MES)-like cells driven by distinct transcription factor networks. Here, we investigate the expression of immunotherapeutic targets in each neuroblastoma subtype and propose pan-neuroblastoma and cell state-specific targetable cell surface proteins.
Methods
We characterized cell lines, patient-derived xenografts, and patient samples as ADRN-dominant or MES-dominant to define subtype-specific and pan-neuroblastoma gene sets. Targets were validated with ChIP-sequencing, immunoblotting, and flow cytometry in neuroblastoma cell lines and isogenic ADRN-to-MES transition cell line models. Finally, we evaluated the activity of MES-specific agents in vivo and in vitro.
Results
Most immunotherapeutic targets being developed for neuroblastoma showed significantly higher expression in the ADRN subtype with limited expression in MES-like tumor cells. In contrast, CD276 (B7-H3) and L1CAM maintained expression across both ADRN and MES states. We identified several receptor tyrosine kinases (RTKs) enriched in MES-dominant samples and showed that AXL targeting with ADCT-601 was potently cytotoxic in MES-dominant cell lines and showed specific antitumor activity in a MES cell line-derived xenograft.
Conclusions
Immunotherapeutic strategies for neuroblastoma must address the potential of epigenetic downregulation of antigen density as a mechanism for immune evasion. We identified several RTKs as candidate MES-specific immunotherapeutic target proteins for the elimination of therapy-resistant cells. We hypothesize that the phenomena of immune escape will be less likely when targeting pan-neuroblastoma cell surface proteins such as B7-H3 and L1CAM, and/or dual targeting strategies that consider both the ADRN and MES cell states.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- ADC Therapeutics (UK) Ltd, London, UK.
- Ludwig Institute for Cancer Research, New York, New York, USA.
ORCID-Profile: Nathan M Kendsersky, Nathaniel W Mabe, Alvin Farrel, David Groff, Adam J Wolpaw, Francesca Zammarchi, Chi V Dang, Kimberly Stegmaier, John M Maris
Förderung
- NCI NIH HHS
- Giulio D'Angio Endowed Chair
- Cancer Pediatric Dream Team Translational Research Grant
- Department of Defense Career Development Award
- Giulio D’Angio Endowed Chair
Zitieren
APA
Kendsersky, N. M., Odrobina, M., Mabe, N. W., Farrel, A., Grossmann, L., Tsang, M., Groff, D., Wolpaw, A. J., Narch, A., Zammarchi, F., van Berkel, P. H., Dang, C. V., Mossé, Y. P., Stegmaier, K., & Maris, J. M. (2025). Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets. Neuro-Oncology, 27(5), 1372-1384. https://doi.org/10.1093/neuonc/noaf012
Vancouver
Kendsersky NM, Odrobina M, Mabe NW, Farrel A, Grossmann L, Tsang M, et al. Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets. Neuro-Oncology. 2025;27(5):1372-1384. doi:10.1093/neuonc/noaf012
BibTeX
@article{Kendsersky2025,
author = {Kendsersky, Nathan M and Odrobina, Michal and Mabe, Nathaniel W and Farrel, Alvin and Grossmann, Liron and Tsang, Matthew and Groff, David and Wolpaw, Adam J and Narch, Alaa and Zammarchi, Francesca and van Berkel, Patrick H and Dang, Chi V and Mossé, Yaël P and Stegmaier, Kimberly and Maris, John M},
title = {Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {5},
pages = {1372--1384},
doi = {10.1093/neuonc/noaf012}
}
EUVIMED